Evidence map›Paper›PMID 41926459›Full record

ArticlePLoS genetics2026

DNMT1 loss leads to hypermethylation of a subset of late replicating domains by DNMT3A.

Ioannis Kafetzopoulos, Francesca Taglini, Moira Pasquier, Hazel Davidson-Smith, Christine J Rodger, Lucia Puchades Gimeno, Andrew A Malcolm, Duncan Sproul

Abstract read
In one paragraph

Article in PLoS genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ioannis KafetzopoulosInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
Francesca TagliniInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
Moira PasquierMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0009-0007-1957-2120
Hazel Davidson-SmithInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
Christine J RodgerMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0001-6318-7923
Lucia Puchades GimenoMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0009-0003-5271-7951
Andrew A MalcolmInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0001-6240-7701
Duncan SproulInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0001-6168-4563

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of DNA methylation is a hallmark of cancer that is proposed to promote carcinogenesis through gene expression alterations, retrotransposon activation and induction of genomic instability. Cancer-associated hypomethylation does not occur across the whole genome but leads to the formation of partially methylated domains (PMDs). However, the mechanisms underpinning PMD formation remain unclear. PMDs replicate late in S-phase leading to the hypothesis that they become hypomethylated due to incomplete re-methylation by the maintenance methyltransferase DNMT1 during cell division. Here we investigate the role of DNMT1 in shaping the cancer methylome by conducting whole genome bisulfite sequencing (WGBS), repli-seq and ChIP-seq on DNMT1 knockout HCT116 colorectal cancer cells (DNMT1 KO cells). We find that DNMT1 loss leads to preferential hypomethylation in late replicating, heterochromatic PMDs marked by the constitutive heterochromatic mark H3K9me3 or the facultative heterochromatic mark H3K27me3. However, we also observe that a subset of H3K9me3-marked PMDs gain methylation in DNMT1 KO cells. We find that, in DNMT1 KO cells, these hypermethylated PMDs remain late replicating but DNMT3A localises to them. This is accompanied by loss of heterochromatic H3K9me3, specific gain of euchromatic H3K36me2 and some gene upregulation. These same domains also have more variable DNA methylation than other PMDs in colorectal tumours in vivo. Our observations suggest that hypermethylated PMDs lose their heterochromatic state, enabling their methylation by DNMT3A and the establishment of a hypermethylated, non-PMD state, despite their late replication timing. More generally, our findings suggest that differential de novo DNMT activity plays a key role in establishing domain level DNA methylation patterns in cancer cells.

Indexed as

Colorectal NeoplasmsDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA ReplicationDNA Methyltransferase 3AGene Expression Regulation, NeoplasticGenomic InstabilityHCT116 CellsHeterochromatinHistonesHumansDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT1 protein, humanDNMT3A protein, humanHeterochromatinHistones

Identifiers

PMID41926459
PMCPMC13061326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.